Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Passive antibody transfer" is **not a molecule or receptor**, but rather a process in which preformed antibodies are given to an individual to provide immediate, short-term immunity against specific pathogens or toxins. This can occur naturally—such as maternal IgG transferred to the fetus via the placenta—or artificially through administration of antibody-containing products like immune globulin or monoclonal antibodies[1][2][3]. The process does not stimulate the recipient's own immune system to produce memory cells; thus, protection is temporary and wanes within weeks to months. Passive antibody transfer is used for rapid prophylaxis in cases such as exposure to infectious diseases or for individuals with immunodeficiencies. Notable risks include hypersensitivity reactions and serum sickness when using animal-derived products[1]. Because it describes an **immunological intervention** rather than a discrete molecular entity, it should not be classified as a therapeutic target such as a receptor, enzyme, transporter, etc.[1][3]
Direct neutralization of pathogens or toxins by transferred antibodies[1][3]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Passive antibody transfer.